Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Next-generation Sequencing

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....

Sanger Sequencing

Sanger Sequencing

DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Maxam-Gilbert Sequencing

Maxam-Gilbert Sequencing

In the same year as the discovery of the Sanger sequencing method, another group of scientists, Allan Maxam and Walter Gilbert, demonstrated their chemical-cleavage method for DNA sequencing. The Maxam-Gilbert method relies on using different chemicals that can cleave the DNA sequence at specific sites, the separation of resulting DNA fragments of variable size using electrophoresis, and deciphering the DNA sequence from the resulting gel bands.
Challenges of the Maxam-Gilbert Method
The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe.

ESMO open·2023

Same author

[iCCA: a new diagnostic approach for a new therapeutic management!]

Annales de pathologie·2022

Same author

A novel lipase with dual localisation in Trypanosoma brucei.

Scientific reports·2022

Same author

Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future.

ESMO open·2021

Same author

Major response to temozolomide as first-line treatment for newly-diagnosed DDR2-mutated glioblastoma: A case report.

Revue neurologique·2020

Same author

Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report.

BMC cancer·2020

Search research articles

Related Experiment Video

Updated: Feb 23, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

[Tumour sequencing: Evolutions and revolutions].

N Piton¹, A Lamy¹, J-C Sabourin¹

¹Service de pathologie, hôpital Charles-Nicolle, Normandie université, CHU de Rouen, 1, rue de Germont, 76031 Rouen, France; Inserm U1245, 1, rue de Germont, 76000 Rouen, France.

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique

|September 12, 2017

Summary

Genomic analysis of tumors, or tumor genotyping, is revolutionizing cancer care by guiding therapy choices and improving diagnosis. The main challenge now lies in interpreting these genetic findings for better patient outcomes.

Keywords:

Facteurs théranostiques Gene panel INCa NGS Next generation sequencing (NGS)Panel de gènes Solid tumours Séquençage de nouvelle génération Theranostic factors Tumeurs solides

More Related Videos

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Related Experiment Videos

Last Updated: Feb 23, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Published on: October 18, 2013

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Area of Science:

Oncology
Genomics
Bioinformatics

Background:

The genomic era has transformed cancer care, enabling detailed tumor genotyping.
Technological advancements facilitate genomic analysis in clinical settings, impacting patient management.

Purpose of the Study:

To highlight the advancements and challenges in tumor genotyping for clinical applications.
To emphasize the shift from detecting molecular alterations to interpreting their clinical significance.

Main Methods:

Genomic analysis of formalin-fixed paraffin-embedded tissues.
Emerging techniques like liquid biopsies for cancer genotyping.
Routine gene panel genotyping using high-throughput sequencing.

Main Results:

Tumor genotyping significantly influences therapeutic decisions, diagnosis, and disease monitoring.
High-throughput sequencing enables routine genotyping for specific cancer types.
Liquid biopsies offer a promising alternative for genomic analysis.

Conclusions:

Tumor genotyping is increasingly integrated into routine medical practice.
The primary challenge in cancer genomics has evolved to the interpretation of molecular alterations.
Accurate interpretation of genetic data is crucial for optimizing patient care and treatment strategies.